Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
BioProcess Internation...BioProcess International US West
Not Confirmed
Not Confirmed
09-11 March, 2026
BioProcess Internation...BioProcess International
Not Confirmed
Not Confirmed
09-11 March, 2026
Not Confirmed
Not Confirmed
09-11 March, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BioProcess Internation...BioProcess International US West
Industry Trade Show
Not Confirmed
09-11 March, 2026
BioProcess Internation...BioProcess International
Industry Trade Show
Not Confirmed
09-11 March, 2026
Industry Trade Show
Not Confirmed
09-11 March, 2026
Digital content

27 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/27/3246782/0/en/Arcutis-Management-to-Present-at-TD-Cowen-s-46th-Annual-Health-Care-Conference.html

25 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/25/3244953/0/en/Arcutis-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html

05 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/05/3233407/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

02 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/02/3230196/0/en/Arcutis-Announces-Positive-Topline-Results-for-INTEGUMENT-INFANT-Phase-2-Trial-of-ZORYVE-roflumilast-Cream-0-05-in-Infants-with-Mild-to-Moderate-Atopic-Dermatitis.html

26 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/26/3225575/0/en/Arcutis-Biotherapeutics-Inc-Announces-Termination-of-Promotion-Agreement-with-Kowa.html

22 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/22/3224241/0/en/Arcutis-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Present-at-Upcoming-Investor-Conference.html
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE